2227484-71-9
2227484-71-9
Chemical Structure
ETD001
- CAS No.: 2227484-71-9
- Formula:C41H57F6N9O16
- Molecular Weight:1045.93
InChIKey: KMKTYTISJOKXPA-NKVRUFHASA-N
SMILES: OC(C(F)(F)F)=O.[O-]C(C(F)(F)F)=O.CC[N+](C1=C2)=C(CNC(C3=C(N)N=C(NC=C4)C4=N3)=O)N(CC)C1=CC=C2C(N5CCC(CC5)N(C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)=O
Biological Activity:
ETD001 is a long-acting ENaC inhibitor, with an IC50 of 57.5 nM in cultured HBE cells. ETD001 can be used in the study for cystic fibrosis[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
ETD001 | 98.85% | ETD001 is a long-acting ENaC inhibitor, with an IC50 of 57.5 nM in cultured HBE cells. ETD001 can be used in the study for cystic fibrosis. |
||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Henry Danahay, et al. Optimisation of a novel series of ENaC inhibitors, leading to the selection of the long-acting inhaled clinical candidate ETD001, a potential new treatment for cystic fibrosis. Eur J Med Chem. 2025 Jan 15:282:117040. [Content Brief]
- [2]. Henry Danahay, et al. ETD001: A novel inhaled ENaC blocker with an extended duration of action in vivo. J Cyst Fibros. 2024 Jun 7:S1569-1993(24)00081-X. [Content Brief]
